



Blue Cross
Blue Shield
Blue Care Network
of Michigan

Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Provider alert

Medicare Plus BlueSM and BCN AdvantageSM

Categories: Authorizations/referrals, Pharmacy

Date posted: Feb. 19, 2025

Update: Step therapy won't be required for Darzalex Faspro

On Feb. 6, 2025, we published a provider alert stating that Darzalex Faspro[®] (daratumumab and hyaluronidase-fihj), HCPCS code J9144, would require step therapy starting May 1, 2025.

However, we've put this change on hold. We aren't adding a step therapy requirement for Darzalex Faspro for Medicare Advantage members at this time.

We apologize for any confusion caused by this change.

[Subscribe](#) to Provider Alerts Weekly, a weekly email with a list of links to the previous week's provider alerts.